Trials / Completed
CompletedNCT06599463
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 351 (actual)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
LARENA is a multicentric retrospective study (secondary use of data) of consecutive patients prospectively registered in the lenvatinib plus pembrolizumab French early access program (Temporary Authorisation for Use). The source of data will be the patient's medical file. We will manually review all files of the participating centers.
Conditions
Timeline
- Start date
- 2024-08-19
- Primary completion
- 2025-02-28
- Completion
- 2025-02-28
- First posted
- 2024-09-19
- Last updated
- 2025-03-20
Locations
24 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06599463. Inclusion in this directory is not an endorsement.